Merck Sues To Shut Out Watson's Generic Propecia

Law360, New York (August 21, 2012, 6:05 PM EDT) -- Merck Sharp & Dohme Corp. lodged a patent infringement suit Monday in New Jersey federal court in an effort to block Watson Laboratories Inc.'s plans to release a generic version of Merck’s male hair growth treatment Propecia.

In a complaint filed in New Jersey federal court, Merck says it brought the suit after Watson sought federal approval of an abbreviated new drug application to make and sell a generic version of Propecia, in violation of Merck’s two patents covering the baldness treatment. 

“Because Watson seeks approval...
To view the full article, register now.